Dr Liu on the Frequency of Activating ERBB2 and ERBB3 Alterations in NSCLC
September 22nd 2023Dazhi Liu, PharmD, MS, BCOP, discusses findings from a real-world analysis of the frequency of ERBB2 and ERBB3 alterations in patients with non–small cell lung cancer and the efficacy of liquid vs tissue biopsies for detecting these alterations.
Read More